|
||||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||
|
||||||||||||
Within
the health system there appears to be a continuing trend towards increasing
costs of treatments despite a declining total health budget. Therefore the costs of treatments and the resulting
outcomes are being assessed. A
treatment must be cost effective both in terms of the input cost and
the output of the clinical result, in order to compete for a finite
slice of the health cake. Thus a common yardstick is needed to compare
each treatment with another.
The
Quality Adjusted Life Year (QALY) is one way in which various unrelated
treatments can be compared. A QALY is based upon a quality
of life score (QOL) from 0 to
1,
with ‘0’ being equivalent to death and ‘1’ to perfect health. One QALY unit represents a year spent in perfect
health. The costs of treatments
are calculated and then divided by the increased amount of QALY’s that have been generated, to obtain a cost/QALY.
An efficient treatment will generate positive QALY’s at a low
cost/QALY.
Our
aim was to determine the cost effectiveness of two different regimes
for the conservative treatment of urinary incontinence. In particular was it more cost effective to send patients to a Nurse
Continence Advisor (NCA) or to the Urogynaecologist (UG), in terms
of cost, objective outcomes and improvement in quality of life?
Methods:
Quality
of life was assessed using a validated QOL/QALY questionnaire, the
York Questionnaire (1). Patients
were prospectively randomised to treatment with either a UG (N= 76)
or a NCA (N= 74).Inclusion criteria were urodynamically proven GSI,
GSI/DI or DI with a one hour pad test loss of 2- 50 grams.
Randomisation was stratified into mild urinary incontinence
(pad test 2-9.9 g) or moderate urinary incontinence (pad test 10-50
g). Exclusion criteria were: absent pad test loss
or severe pad test loss (>50g), prolapse beyond the introitus,
malignancy, voiding difficulty, ring
pessary in-situ, recurrent cystitis, and residence outside the metropolitan
area. These exclusions were made to ensure that the patients did not
have other confounding gynaecological problems, and that they were
able to regularly attend for intensive weekly treatment if so randomised.
The
UG group was given routine instruction regarding pelvic floor exercises,
bladder training, and given vaginal cone weights or anticholinergic
drugs when clinically indicated.
Patients were also referred to an “outside” physiotherapist
if their pelvic floor tone was very weak or acontractile.
The equation for calculating cost was: [trips to the
unit x trip cost] – [cost saved on pads/month x 13 x 4.2124] + [clinician
costs] + [drug costs/month x 13 x 4.2124] + [administrative costs/hr
x hours of visit] + [investigation costs] + [lost time from work x
trips to the unit].
Results:
There were no significant differences between the two groups at baseline. A number of patients did not complete the study (N= 55), with a significantly greater number not completing the UG treatment. The objective outcomes and QOL improved significantly from baseline, with no significant differences between the two groups at three months. The NCA’s spent significantly longer with their patients, as would be expected from the trial design, however did not cost significantly more owing to their reduced hourly wage (A$22 vs A$80). The final cost/QALY revealed that the NCA treatment was significantly more cost effective than the UG.
|
|
NCA (N= 76) |
UG (N= 74) |
P Value |
|
Withdrawls from the study Age (years) Parity Weight (kgs) Reduction in leaks/week Reduction in Pad Test (g/hr) QOL gain (%) Reduction of Pad Cost (A$) Clinician Time (minutes) Clinician Cost (A$) Total Cost (A$) Cost/QALY |
21 57.7 2.59 70.8 8.5 3.3 1.51 2.90 186 68.21 910 28,009 |
34 59.3 2.72 74.4 13.0 2.4 1.21 3.52 62 97.70 901 35,312 |
0.03 NS NS NS NS NS NS NS 0.0001 0.001 NS 0.03 |
Conclusions:
The NCA treatment was more cost effective than the UG both in terms of the cost/QALY and also in terms of compliance to the treatment program.
References:
1. A scale of valuations of states
of illnesses. Int J Epid 1978;7:347-58
2. Foundations
of cost effectiveness analysis for health and medical practise. NEJM 1977;303:308-16